Inflammatory Bowel Diseases

Skip Navigation LinksHome > May 2013 - Volume 19 - Issue 6 > Tacrolimus Salvage in Anti–Tumor Necrosis Factor Antibody Tr...
Text sizing:
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e318280b154
Original Clinical Article

Tacrolimus Salvage in Anti–Tumor Necrosis Factor Antibody Treatment-Refractory Crohn’s Disease

Gerich, Mark E. MD*; Pardi, Darrell S. MD; Bruining, David H. MD; Kammer, Patricia P. CCRP; Becker, Brenda D.; Tremaine, William T. MD

Collapse Box


Background: Several small retrospective studies have reported encouraging response rates in patients with Crohn’s disease (CD) treated with tacrolimus.

Methods: We conducted a retrospective study of the use of oral tacrolimus for severe CD refractory to anti–tumor necrosis factor agents. Response was defined as a clinician’s assessment of improvement after at least 7 days of treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well-being. Remission required all of the following: <3 stools per day, no bleeding, abdominal pain or extraintestinal manifestations, and increased well-being.

Results: Twenty-four eligible patients were treated with tacrolimus for a median of 4 months. Approximately 37% were steroid dependent or steroid refractory. Response and steroid-free remission rates were 67% and 21%, respectively, and lasted for a median of 4 months. Approximately 42% of patients were able to stop steroids and 54% of patients ultimately required surgery within a median of 10 months after starting tacrolimus. Patients with mean tacrolimus trough levels of 10 to 15 ng/mL had the highest rates of response (86%) and remission (57%). Surgery seemed to be postponed in this group compared with others. An adverse event occurred in 75% of patients. Eight of these events (33%) required dose reduction and 6 (25%) led to treatment discontinuation. There were no irreversible side effects or deaths attributable to tacrolimus over a median follow-up of 56 months.

Conclusions: Oral tacrolimus seems to be safe and effective in some patients with severe CD refractory to anti–tumor necrosis factor therapy, particularly at a mean trough level of 10 to 15 ng/mL.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.